Compounds > resiquimod
Page last updated: 2024-09-04

resiquimod and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine

resiquimod has been researched along with 1-hexadecyl-2-acetyl-glycero-3-phosphocholine in 1 studies

Compound Research Comparison

Studies
(resiquimod)		Trials
(resiquimod)		Recent Studies (post-2010)
(resiquimod)		Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
465143189,156187552

Protein Interaction Comparison

ProteinTaxonomyresiquimod (IC50)1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50)
Platelet-activating factor receptorHomo sapiens (human)0.0003

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Borgeat, M; Borgeat, P; Hattermann, K; Leclerc, P; Picard, S; Pouliot, M1

Other Studies

1 other study(ies) available for resiquimod and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine

ArticleYear
The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2007, Volume: 21, Issue:7

    Topics: Dinoprostone; Humans; Imidazoles; Inflammation Mediators; Leukotriene B4; Neutrophils; Platelet Activating Factor; RNA Viruses; Signal Transduction; Toll-Like Receptor 7; Toll-Like Receptor 8

2007